281 related articles for article (PubMed ID: 31502148)
21. Biomarkers for Immunotherapy: Current Developments and Challenges.
Spencer KR; Wang J; Silk AW; Ganesan S; Kaufman HL; Mehnert JM
Am Soc Clin Oncol Educ Book; 2016; 35():e493-503. PubMed ID: 27249758
[TBL] [Abstract][Full Text] [Related]
22. Accelerating the Development of Personalized Cancer Immunotherapy by Integrating Molecular Patients' Profiles with Dynamic Mathematical Models.
Agur Z; Elishmereni M; Foryś U; Kogan Y
Clin Pharmacol Ther; 2020 Sep; 108(3):515-527. PubMed ID: 32535891
[TBL] [Abstract][Full Text] [Related]
23. RNA Sequencing of the Tumor Microenvironment in Precision Cancer Immunotherapy.
Lau D; Bobe AM; Khan AA
Trends Cancer; 2019 Mar; 5(3):149-156. PubMed ID: 30898262
[TBL] [Abstract][Full Text] [Related]
24. Investigation of clinically relevant germline variants detected by next-generation sequencing in patients with childhood cancer: a review of the literature.
Sylvester DE; Chen Y; Jamieson RV; Dalla-Pozza L; Byrne JA
J Med Genet; 2018 Dec; 55(12):785-793. PubMed ID: 30287599
[TBL] [Abstract][Full Text] [Related]
25. Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology.
Peskov K; Azarov I; Chu L; Voronova V; Kosinsky Y; Helmlinger G
Front Immunol; 2019; 10():924. PubMed ID: 31134058
[TBL] [Abstract][Full Text] [Related]
26. Cancer Predisposition Sequencing Reporter (CPSR): A flexible variant report engine for high-throughput germline screening in cancer.
Nakken S; Saveliev V; Hofmann O; Møller P; Myklebost O; Hovig E
Int J Cancer; 2021 Dec; 149(11):1955-1960. PubMed ID: 34310709
[TBL] [Abstract][Full Text] [Related]
27. Transforming Cancer Prevention through Precision Medicine and Immune-oncology.
Kensler TW; Spira A; Garber JE; Szabo E; Lee JJ; Dong Z; Dannenberg AJ; Hait WN; Blackburn E; Davidson NE; Foti M; Lippman SM
Cancer Prev Res (Phila); 2016 Jan; 9(1):2-10. PubMed ID: 26744449
[TBL] [Abstract][Full Text] [Related]
28. A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery.
Creemers JHA; Lesterhuis WJ; Mehra N; Gerritsen WR; Figdor CG; de Vries IJM; Textor J
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34059522
[TBL] [Abstract][Full Text] [Related]
29. The Clinical Relevance of Frequent Germline Genetic Variants Detected by Targeted Sequencing in Patients With Rectal Adenocarcinoma (READ).
Huang KC; Chiang SF; Ke TW; Chen WT; Chen TW; Chao KC
Cancer Genomics Proteomics; 2020; 17(3):291-299. PubMed ID: 32345670
[TBL] [Abstract][Full Text] [Related]
30. A decision support framework for genomically informed investigational cancer therapy.
Meric-Bernstam F; Johnson A; Holla V; Bailey AM; Brusco L; Chen K; Routbort M; Patel KP; Zeng J; Kopetz S; Davies MA; Piha-Paul SA; Hong DS; Eterovic AK; Tsimberidou AM; Broaddus R; Bernstam EV; Shaw KR; Mendelsohn J; Mills GB
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863335
[TBL] [Abstract][Full Text] [Related]
31. Identifying MicroRNA Pathway Variants as Biomarkers of Patient Selection for Immune Therapy.
Weidhaas JB
Methods Mol Biol; 2020; 2055():203-212. PubMed ID: 31502153
[TBL] [Abstract][Full Text] [Related]
32. Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology.
DiNatale RG; Hakimi AA; Chan TA
Hum Mol Genet; 2020 Oct; 29(R2):R214-R225. PubMed ID: 33029628
[TBL] [Abstract][Full Text] [Related]
33. Genomics and emerging biomarkers for immunotherapy of colorectal cancer.
Kather JN; Halama N; Jaeger D
Semin Cancer Biol; 2018 Oct; 52(Pt 2):189-197. PubMed ID: 29501787
[TBL] [Abstract][Full Text] [Related]
34. Prostate cancer: germline prediction for a commonly variable malignancy.
Bambury RM; Gallagher DJ
BJU Int; 2012 Dec; 110(11 Pt C):E809-18. PubMed ID: 22974436
[TBL] [Abstract][Full Text] [Related]
35. The pan-cancer landscape of prognostic germline variants in 10,582 patients.
Chatrath A; Przanowska R; Kiran S; Su Z; Saha S; Wilson B; Tsunematsu T; Ahn JH; Lee KY; Paulsen T; Sobierajska E; Kiran M; Tang X; Li T; Kumar P; Ratan A; Dutta A
Genome Med; 2020 Feb; 12(1):15. PubMed ID: 32066500
[TBL] [Abstract][Full Text] [Related]
36. Coming of Age: Human Genomics and the Cancer-Immune Set Point.
Hammer C; Mellman I
Cancer Immunol Res; 2022 Jun; 10(6):674-679. PubMed ID: 35471657
[TBL] [Abstract][Full Text] [Related]
37. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
Mandelker D; Zhang L; Kemel Y; Stadler ZK; Joseph V; Zehir A; Pradhan N; Arnold A; Walsh MF; Li Y; Balakrishnan AR; Syed A; Prasad M; Nafa K; Carlo MI; Cadoo KA; Sheehan M; Fleischut MH; Salo-Mullen E; Trottier M; Lipkin SM; Lincoln A; Mukherjee S; Ravichandran V; Cambria R; Galle J; Abida W; Arcila ME; Benayed R; Shah R; Yu K; Bajorin DF; Coleman JA; Leach SD; Lowery MA; Garcia-Aguilar J; Kantoff PW; Sawyers CL; Dickler MN; Saltz L; Motzer RJ; O'Reilly EM; Scher HI; Baselga J; Klimstra DS; Solit DB; Hyman DM; Berger MF; Ladanyi M; Robson ME; Offit K
JAMA; 2017 Sep; 318(9):825-835. PubMed ID: 28873162
[TBL] [Abstract][Full Text] [Related]
38. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
Wellmann R; Borden BA; Danahey K; Nanda R; Polite BN; Stadler WM; Ratain MJ; O'Donnell PH
Cancer; 2018 Jul; 124(14):3052-3065. PubMed ID: 29742281
[TBL] [Abstract][Full Text] [Related]
39. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
40. Current Challenges in Cancer Treatment.
Zugazagoitia J; Guedes C; Ponce S; Ferrer I; Molina-Pinelo S; Paz-Ares L
Clin Ther; 2016 Jul; 38(7):1551-66. PubMed ID: 27158009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
